Back
For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".
To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".
During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center.
Preparing your E-Poster
Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.
E-Poster Submission Deadline
Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.
Please follow the instructions below to input your abstract title.
Abstract titles should be brief and reflect the content of the abstract.
South Africa has one of the highest prevalences of human immunodeficiency virus (HIV) infection worldwide. Kidney disease is a common and important complication of HIV, and a wide spectrum of kidney pathology associated with HIV infection has been described, with human immunodeficiency virus-associated nephropathy (HIVAN) the most well-characterised and historically the most prevalent. However, since the introduction of antiretroviral therapy (ART) in South Africa in 2004, the patterns of HIV-related kidney pathology have changed. This study aims to describe the spectrum of kidney pathology among people living with HIV who underwent kidney biopsy over a 29-year period at a tertiary hospital in Cape Town, South Africa, and to describe patterns of kidney pathology before and after the rollout of ART.
This retrospective, descriptive study included people living with HIV who underwent native kidney biopsy at Tygerberg Hospital during the period of 1 January 1992 to 31 December 2020. Clinico-demographic and laboratory data were obtained from the institutional kidney biopsy registry and the National Health Laboratory Service (NHLS). We describe the frequencies and proportions of histopathological patterns of kidney injury in the overall cohort and compare their distribution before (1992-2003) and after the rollout of ART (2004-2020). The most common non-HIVAN histopathological patterns were also identified.
The cohort consisted of 554 people living with HIV who underwent kidney biopsy during the study period. Most biopsies were done after the ART rollout began (499 out of 554, 90.1%). The mean age at biopsy was 36.5 years with a relatively equal distribution by sex. Data on ART use were unavailable for patients in the pre-ART period, but were available for most patients in the post-ART rollout period, of whom 54.8% (232/423) were using ART at the time of biopsy. HIV-associated nephropathy (HIVAN) was diagnosed in 45.7% of all patients (253/554), with one-third of those with HIVAN (84/253, 33.2%) having an additional histopathological pattern of injury. In the pre-ART rollout period, HIVAN was the most prevalent diagnosis (33/55, 60.0%), whereas a lower prevalence was observed post-ART rollout (220/499, 44.1%). During the post-ART rollout period, more than half of the patients (279/499, 55.9%) exhibited only non-HIVAN kidney pathology. The most frequently observed non-HIVAN histopathological patterns were immune-complex glomerulonephritis (181/384, 47.1%) and tubulointerstitial disease (153/384, 39.8%). In an exploratory analysis, ART use was associated with a lower odds of HIVAN only (aOR=0.39, 95% CI 0.24-0.64) after adjustment for case mix.
This study described the spectrum of kidney pathology amongst patients with HIV at a tertiary centre in Cape Town, South Africa, over nearly three decades, demonstrating a substantial burden of HIVAN overall. Unsurprisingly, we observed a lower proportion of patients with HIVAN in the post-ART rollout period compared to the period before ART rollout. An increase in the proportion of patients with non-HIVAN pathology, most notably immune-complex glomerulonephritis and tubulointerstitial disease, accompanied the decrease in the proportion of patients with HIVAN in the period after ART rollout.
